CarryGenes Therapeutics
CarryGenes focuses on developing transformative cell-based drugs, leveraging a fusion of expertise in immunotherapy, biomedical sciences, and chromosome bioengineering. Their innovative chromosome platform aims to revolutionize treatment for serious diseases, including cancer, through gene therapy and immunotherapy approaches. The company operates in both Sweden and the United States, with a focus on rapid development collaborations and licensing deals to bring therapies to market.
Industries
Nr. of Employees
small (1-50)
Products
Synthetic chromosome carrier for antitumor transgene delivery
A synthetic human chromosome designed as a genomic carrier to deliver antitumor genetic payloads into patient T cells to enable long-term, multi-gene expression in engineered immune cells.
Library of vectors and experimental reagents
A curated collection of genetic vectors, molecular reagents, and experimental tools intended to support development and testing of engineered cell constructs.
Synthetic chromosome carrier for antitumor transgene delivery
A synthetic human chromosome designed as a genomic carrier to deliver antitumor genetic payloads into patient T cells to enable long-term, multi-gene expression in engineered immune cells.
Library of vectors and experimental reagents
A curated collection of genetic vectors, molecular reagents, and experimental tools intended to support development and testing of engineered cell constructs.
Services
Partner-based development agreements and licensing arrangements to advance cell therapy programs and technology platforms.
Research and preclinical development activities focused on designing and testing engineered immune cells using chromosome-based gene delivery and associated tools.
Partner-based development agreements and licensing arrangements to advance cell therapy programs and technology platforms.
Research and preclinical development activities focused on designing and testing engineered immune cells using chromosome-based gene delivery and associated tools.
Expertise Areas
- Chromosome-based immunotherapies
- Cell therapy development
- Ex vivo T-cell engineering
- CAR design and multiplexing
Key Technologies
- Synthetic human chromosome-based gene delivery
- Chimeric antigen receptor (CAR) multiplexing
- Chemokine receptor engineering
- Cell sorting via CD34 marker